SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report)’s share price passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $7.68 and traded as high as $7.91. SOPHiA GENETICS shares last traded at $7.86, with a volume of 918,997 shares traded.
Wall Street Analysts Forecast Growth
SOPH has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, October 15th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research raised their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, HC Wainwright restated a “buy” rating and issued a $14.00 price objective on shares of SOPHiA GENETICS in a report on Monday, October 12th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, SOPHiA GENETICS currently has a consensus rating of “Hold” and a consensus price target of $10.00.
Get Our Latest Stock Analysis on SOPH
SOPHiA GENETICS Price Performance
The company has a quick ratio of 2.16, a current ratio of 2.29 and a debt-to-equity ratio of 0.70. The firm’s fifty day moving average price is $7.68 and its two-hundred day moving average price is $6.01. The stock has a market capitalization of $659.38 million, a PE ratio of -7.21 and a beta of 1.09.
SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The firm had revenue of $24.27 million during the quarter, compared to the consensus estimate of $24.03 million. SOPHiA GENETICS had a negative net margin of 89.18% and a negative return on equity of 128.69%. On average, equities analysts predict that SOPHiA GENETICS SA will post -0.94 earnings per share for the current year.
Insider Transactions at SOPHiA GENETICS
In other SOPHiA GENETICS news, Chairman Jurgi Camblong sold 8,500 shares of the firm’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $7.26, for a total value of $61,710.00. Following the completion of the sale, the chairman owned 3,387,150 shares of the company’s stock, valued at $24,590,709. This trade represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Philippe Menu sold 5,000 shares of the stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $7.26, for a total value of $36,300.00. Following the completion of the sale, the insider owned 195,993 shares in the company, valued at approximately $1,422,909.18. The trade was a 2.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 157,162 shares of company stock worth $1,270,334. 4.88% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Maven Securities LTD bought a new stake in SOPHiA GENETICS during the 2nd quarter valued at $866,000. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS in the 2nd quarter worth $9,809,000. Sowell Financial Services LLC bought a new position in shares of SOPHiA GENETICS during the 3rd quarter worth $2,865,000. Sei Investments Co. bought a new position in shares of SOPHiA GENETICS during the 1st quarter worth $1,772,000. Finally, Hennion & Walsh Asset Management Inc. purchased a new position in shares of SOPHiA GENETICS during the second quarter valued at $567,000. Institutional investors own 31.59% of the company’s stock.
SOPHiA GENETICS Company Profile
SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.
Read More
- Five stocks we like better than SOPHiA GENETICS
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
-sae-logo-1200x675.png){kind=logo}
